Nanjing Leads Biolabs Co., Ltd. (9887.HK) has received FDA approval for its first-in-human Investigational New Drug (IND) application for LBL-047, a bispecific fusion protein targeting BDCA2 and TACI. LBL-047 is the first clinical trial worldwide to focus on both BDCA2 and TACI, showing strong potential as a first-in-class treatment option. For more health news, visit rttnews.com.

Read more at Nasdaq: FDA Approves IND For Nanjing Leads Biolabs’ LBL-047, Bispecific Targeting BDCA2 And TACI